Munich-based Twogee Biotech has secured €2.2M in seed funding to industrialize its enzyme-based platform for converting biomass residues into sustainable, second-generation raw materials.
Founded in 2024, Twogee Biotech develops customized enzyme solutions and production strains that enable industrial partners to transform low-value biomass side streams into usable raw materials. The company focuses in particular on second-generation sugars for bio- and synthetic biology applications, offering an alternative to fossil- and food-based inputs.
Enzyme development with an industrial mindset
Twogee’s predictive development platform integrates enzyme screening, strain engineering, and fermentation from the outset with industrial scalability in mind. This approach shortens development cycles and reduces risks during scale-up, allowing partners to build circular, low-CO₂ value chains from previously underutilized biomass streams.
The company has already completed initial MVPs, launched paid pilot projects with industry partners, and established in-house laboratories and bioreactor infrastructure in Munich.
Advertisement
Backed by biotech and strategic industry investors
The €2.16M seed round includes High-Tech Gründerfonds and Bayern Kapital, alongside strategic partners AgriFoodTech Venture Alliance and Heinz Entsorgung. The new capital will be used to accelerate technology development, expand laboratory capacity, and advance commercialization.
According to CEO Frank Wallrapp, many industrial residual streams still contain significant untapped commercial value, and Twogee Biotech’s solutions are designed to unlock this potential with minimal integration effort and a clear economic return.
Licensing model and decentralized production
Twogee Biotech plans to pursue a licensing-based business model that allows customers to produce enzymes locally at their own sites. This setup is intended to lower costs, reduce transport-related emissions, and support decentralized, circular production systems.
CTO and co-founder Helge Jochens noted that part of the funding will be invested in expanding predictive bioreactor systems and strengthening the team with process and scale-up experts, ensuring reliable transfer from lab to industrial production.
Positioning as a circular economy enabler
With its seed financing completed, Twogee Biotech positions itself as a long-term technology development partner for industrial companies aiming to convert existing facilities and material streams into circular, low-CO₂ value creation systems.
About Twogee Biotech
Twogee Biotech is a Munich-based biotechnology company founded in 2024. The company develops customized enzyme and strain solutions for the industrial conversion of biogenic side and residual streams into sustainable second-generation raw materials, supporting the chemical industry’s transition toward scalable, circular, and low-emission production models.
